STOCK TITAN

ISEE - ISEE STOCK NEWS

Welcome to our dedicated page for ISEE news (Ticker: ISEE), a resource for investors and traders seeking the latest updates and insights on ISEE stock.

Iveric Bio, Inc. (NASDAQ: ISEE) is a prominent biopharmaceutical company dedicated to the development of innovative therapeutics targeted at diseases affecting the back of the eye. The company's primary focus is on age-related macular degeneration (AMD), a significant cause of vision loss among older adults. Iveric Bio is at the forefront of ophthalmology research, advancing drugs that could potentially transform the treatment landscape for retinal diseases.

One of the company's notable projects is the development of Avacincaptad Pegol, aimed at treating Geographic Atrophy secondary to AMD, a condition that leads to irreversible blindness. This drug is currently in advanced stages of clinical trials, poised to make a substantial impact upon receiving regulatory approval.

In a significant development, on July 11, 2023, Iveric Bio was acquired by Astellas Pharma Inc. (TSE: 4503). This acquisition, valued at approximately $5.9 billion, marks a strategic expansion for Astellas into the ophthalmology sector. The merger combines Iveric Bio's extensive expertise and promising drug pipeline with Astellas' robust global presence and resources, setting the stage for accelerated progress in developing and commercializing treatments for retinal diseases.

Following the acquisition, Iveric Bio's common stock was delisted from NASDAQ. The successful completion of this acquisition signifies a new chapter for Iveric Bio, with enhanced capabilities to bring groundbreaking ophthalmic therapies to market.

Iveric Bio remains committed to its mission of addressing unmet medical needs in eye care through pioneering research and development. As a subsidiary of Astellas, it is well-positioned to leverage combined strengths, promising a future where advancements in treatment for retinal diseases can significantly improve patient outcomes globally.

For more detailed and up-to-date information, investors and stakeholders are encouraged to follow the latest news releases and updates from both Iveric Bio and Astellas Pharma.

Rhea-AI Summary

IVERIC bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The on-demand presentation will be accessible starting September 13 at 7:00 a.m. ET via the Company’s website. IVERIC bio focuses on developing treatments for retinal diseases, particularly age-related and inherited conditions. An archived replay will be available for at least 30 days post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
conferences
-
Rhea-AI Summary

Iveric Bio, Inc. (NASDAQ: ISEE) announced on September 1, 2021, that it granted equity-based awards to three new non-executive employees under its 2019 Inducement Stock Incentive Plan. The grants include non-statutory options for 155,000 shares at an exercise price of $10.45, reflecting the stock's closing price on the grant date. The options vest over four years, with initial vesting on September 1, 2022, and subsequent monthly vesting. Additionally, the company granted 12,500 restricted stock units, which will vest fully on September 1, 2022, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Summary

IVERIC bio (Nasdaq: ISEE) will feature President Pravin U. Dugel, M.D. at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. His presentation will be available on-demand from 7:00 a.m. ET, alongside a live panel discussion titled Addressing Unmet Medical Needs in Macular Degeneration at 11:00 a.m. ET. Investors can tune in via the Iveric Bio website, where an archived replay will be provided for 30 days post-conference. The company focuses on therapies for retinal diseases, including age-related and inherited conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences
Rhea-AI Summary

IVERIC bio (Nasdaq: ISEE) will have its President, Pravin U. Dugel, M.D., participate in a panel on Ophthalmic Gene Therapy at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11 at 8:00 a.m. ET. The event is open to investors and the public via live webcast on the company's website, with an archived replay available for 30 days thereafter. Iveric bio focuses on developing treatments for retinal diseases, with both therapeutic and gene therapy product candidates addressing significant unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
-
Rhea-AI Summary

IVERIC bio, Inc. (Nasdaq: ISEE) reported Q2 2021 financial results, highlighting significant progress in their Zimura clinical program. The company received a Special Protocol Assessment from the FDA for the GATHER2 trial and completed patient enrollment four months ahead of schedule, targeting over 90% retention. They strengthened their balance sheet with a public offering, raising ~$108 million. However, they incurred a net loss of $30.1 million for the quarter. Cash reserves are projected between $215 million and $225 million by year-end 2021, sufficient to fund operations through mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary

IVERIC bio, Inc. (Nasdaq: ISEE) announced the grant of equity-based awards on August 2, 2021, to five newly hired employees as part of its 2019 Inducement Stock Incentive Plan. Significant awards include a non-statutory option to purchase 160,000 shares and restricted stock units totaling 90,000 for Senior VP Christopher Simms, with vesting over various periods. The exercise price for options is set at $8.64 per share, reflecting the stock's closing price on the grant date. These grants aim to incentivize employee retention and align interests.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
Rhea-AI Summary

IVERIC bio, Inc. (Nasdaq: ISEE) will report its Q2 2021 financial results on August 4, 2021. Following the announcement, management will host a live conference call at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Participants can dial in to join or access the audio webcast on the company’s website. Iveric is focused on developing treatments for retinal diseases, including therapeutic and gene therapy candidates for specific conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences earnings
-
Rhea-AI Summary

IVERIC bio (Nasdaq: ISEE) announced the early completion of patient enrollment for the GATHER2 clinical trial of Zimura (avacincaptad pegol), aimed at treating geographic atrophy secondary to age-related macular degeneration. Enrollment was completed four months ahead of schedule, signaling a strong patient need amid the challenges of the COVID-19 pandemic. Topline data is expected in H2 2022, contingent on meeting primary endpoints. The FDA has provided a Special Protocol Assessment for GATHER2, bolstering plans for marketing application if results are favorable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
-
Rhea-AI Summary

IVERIC bio, Inc. (Nasdaq: ISEE) appointed Christopher Simms as Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Simms, previously with Novartis, will focus on developing and implementing the company’s commercial strategy, particularly for Zimura® in the upcoming GATHER2 clinical trial and potential new drug application. His extensive experience in ophthalmology is expected to aid in establishing a successful AMD franchise. Iveric is dedicated to advancing retinal disease treatments, and Simms' appointment marks a pivotal step in transitioning to a commercial organization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
management
Rhea-AI Summary

IVERIC bio, Inc. (Nasdaq: ISEE) announced a public offering of 11,650,000 shares at $8.60 each, raising about $100.2 million before expenses. An option for underwriters to purchase an additional 1,747,500 shares is included. The offering is managed by Cowen, Credit Suisse, and Stifel, with expected closing on July 15, 2021. This move aims to bolster funding for the company’s development of treatments for retinal diseases. All shares are offered by the Company, and the prospectus will be filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags

FAQ

What is the market cap of ISEE (ISEE)?

The market cap of ISEE (ISEE) is approximately 5.5B.

What is Iveric Bio's primary area of focus?

Iveric Bio specializes in developing novel therapeutics for diseases of the back of the eye, with a primary focus on age-related macular degeneration (AMD).

What significant recent event involved Iveric Bio?

On July 11, 2023, Iveric Bio was acquired by Astellas Pharma Inc. for approximately $5.9 billion, becoming a wholly-owned subsidiary.

What is Avacincaptad Pegol?

Avacincaptad Pegol is a therapeutic being developed by Iveric Bio for the treatment of Geographic Atrophy secondary to age-related macular degeneration.

What happened to Iveric Bio's stock following the acquisition by Astellas?

Iveric Bio's common stock was delisted from NASDAQ following the acquisition by Astellas Pharma Inc.

How will the acquisition by Astellas benefit Iveric Bio?

The acquisition combines Iveric Bio's expertise in ophthalmology with Astellas' global resources, enhancing their ability to develop and commercialize treatments for retinal diseases.

Who was the CEO of Iveric Bio prior to the acquisition?

Glenn P. Sblendorio was the CEO of Iveric Bio before its acquisition by Astellas Pharma Inc.

What is the significance of Geographic Atrophy in AMD?

Geographic Atrophy is an advanced form of AMD that leads to irreversible blindness, making it a significant focus for therapeutic development.

What are the future prospects for Iveric Bio under Astellas?

Under Astellas, Iveric Bio is well-positioned to lead in developing and bringing to market differentiated treatments for retinal diseases.

Who is the President of Iveric Bio?

Pravin U. Dugel is the President of Iveric Bio.

Where can I find more information about Iveric Bio and Astellas?

For more detailed information, visit the official websites and follow the latest news releases from both Iveric Bio and Astellas Pharma.

ISEE

Nasdaq:ISEE

ISEE Rankings

ISEE Stock Data

5.51B
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York